Goat Anti-Human Lambda-Alexa Fluor® 488

Cat. No.
1.0 mg  
Price (USD)
Specificity Reacts with human λ light chains
Source Pooled antisera from goats hyperimmunized with human λ light chains
Cross Adsorption Human κ light chains; may react with λ light chains from other species
Purification Affinity chromatography on human λ light chains covalently linked to agarose
Isotype Goat IgG
Isotype Control Goat IgG-Alexa Fluor® 488
Format/Conjugate AF488 (Alexa Fluor® 488)
Buffer Formulation Phosphate buffered saline containing < 0.1% sodium azide
Concentration 1.0 mg/mL
Volume 1.0 mL
Storage & Handling 2-8°C; Avoid exposure to light
Please refer to product specific SDS
Quality tested applications for relevant formats include -
ELISA 1-11
Flow Cytometry 18-20
Other referenced applications for relevant formats include -
ELISpot 12
Immunohistochemistry-Paraffin Sections 13
Immunocytochemistry 14-16
Western Blot 16
Immunoprecipitation 17
Surface Plasmon Resonance 21
Stimulation 22
Recommended Dilutions Please refer to product specific Technical Bulletin
RRID AB_2795757
  • FLISA plate was coated with purified human IgGκ, IgMκ, IgAκ, IgGλ, IgMλ, and IgAλ. Immunoglobulins were detected with serially diluted Goat Anti-Human Lambda-AF488 (SB Cat. No. 2070-30).

FLISA plate was coated with purified human IgGκ, IgMκ, IgAκ, IgGλ, IgMλ, and IgAλ. Immunoglobulins were detected with serially diluted Goat Anti-Human Lambda-AF488 (SB Cat. No. 2070-30).
Related Products (12)
1. Sy MS, Guo Y, Stamenkovic I. Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med. 1991;174:859-66. (ELISA)
2. Houpt DC, Pfrommer GS, Young BJ, Larson TA, Kozel TR. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect Immun. 1994;62:2857-64. (ELISA)
3. Deng Y, Notkins AL. Molecular determinants of polyreactive antibody binding: HCDR3 and cyclic peptides. Clin Exp Immunol. 2000;119:69-76. (ELISA)
4. Pancook JD, Beuerlein G, Pecht G, Tang Y, Nie Y, Wu H, et al. In vitro affinity maturation of human IgM antibodies reactive with tumor-associated antigens. Hybrid Hybridomics. 2001;20:383-96. (ELISA)
5. Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem. 2004;279:6213-6. (ELISA)
6. Tsurushita N, Park M, Pakabunto K, Ong K, Avdalovic A, Fu H, et al. Humanization of a chicken anti-IL-12 monoclonal antibody. J Immunol Methods. 2004;295:9-19. (ELISA)
7. Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J Immunol. 2006;176:346-56. (ELISA)
8. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA. 2006;103:17408-13. (ELISA)
9. Akamatsu Y, Pakabunto K, Xu Z, Zhang Y, Tsurushita N. Whole IgG surface display on mammalian cells: Application to isolation of neutralizing chicken monoclonal anti-IL-12 antibodies. J Immunol Methods. 2007;327:40-52. (ELISA)
10. Guan Y, Sajadi MM, Kamin-Lewis R, Fouts TR, Dimitrov A, Zhang Z, et al. Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc Natl Acad Sci USA. 2009;106:3952-7. (ELISA)
11. Xu Z, Juan V, Ivanov A, Ma Z, Polakoff D, Powers DB, et al. Affinity and cross-reactivity engineering of CTLA4-Ig to modulate T cell costimulation. J Immunol. 2012;189:4470-7. (ELISA)
12. Saletti G, Çuburu N, Yang JS, Dey A, Czerkinsky C. Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood. Nat Protoc. 2013;8:1073-87. (ELISPOT)
13. Bonda DJ, Webber KM, Siedlak SL, Perry G, Friedland RP, Smith MA. The pathology of Alzheimer disease elicits an in vivo immunological response. Am J Immunol. 2007;3:10-14. (IHC-PS)
14. Campana D, Coustan-Smith E, Janossy G. The immunologic detection of minimal residual disease in acute leukemia. Blood. 1990;76:163-71. (ICC)
15. Campana D, Farrant J, Inamdar N, Webster AD, Janossy G. Phenotypic features and proliferative activity of B cell progenitors in X-linked agammaglobulinemia. J Immunol. 1990;145:1675-80. (ICC)
16. Hasegawa H, Forte C, Barber I, Turnbaugh S, Stoops J, Shen M, et al. Modulation of in vivo IgG crystallization in the secretory pathway by heavy chain isotype class switching and N-linked glycosylation. Biochim Biophys Acta. 2014;1843:1325-38. (ICC, WB)
17. Santiago T, Kulemzin SV, Reshetnikova ES, Chikaev NA, Volkova OY, Mechetina LV, et al. FCRLA is a resident endoplasmic reticulum protein that associates with intracellular Igs, IgM, IgG and IgA. Int Immunol. 2011;23:43-53. (IP)
18. Kumagai M, Coustan-Smith E, Murray DJ, Silvennoinen O, Murti KG, Evans WE, et al. Ligation of CD38 suppresses human B lymphopoiesis. J Exp Med. 1995;181:1101-10. (FC)
19. Minegishi Y, Conley ME. Negative selection at the pre-BCR checkpoint elicited by human μ heavy chains with unusual CDR3 regions. Immunity. 2001;14:631-41. (FC)
20. Dühren-von Minden M, Übelhart R, Schneider D, Wossning T, Bach MP, Buchner M, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012;489:309-12. (FC)
21. Wagner K, Kwakkenbos MJ, Claassen YB, Maijoor K, Böhne M, van der Sluijs KF, et al. Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity. Proc Natl Acad Sci USA. 2014;111:16820-5. (Surface Plasmon Resonance)
22. Nechansky A, Robertson MW, Albrecht BA, Apgar JR, Kricek F. Inhibition of antigen-induced mediator release from IgE-sensitized cells by a monoclonal anti-FcεRI α-chain receptor antibody: implications for the involvement of the membrane-proximal α-chain region in FcεRI-mediated cell activation. J Immunol. 2001;166:5979-90. (Stim)
Alexa Fluor® is a registered trademark of Life Technologies Corporation